Similar articles for PMID: 18345711

Year	Number of Results
2000	1
2003	1
2004	7
2005	10
2006	6
2007	12
2008	8
2009	8
2010	7
2011	4
2012	1
2013	3
2014	4
2015	2
2016	2
2017	3
2018	2
2024	0

1

Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers).

Coca A. Coca A. Clin Drug Investig. 2008;28(4):211-20. doi: 10.2165/00044011-200828040-00002. Clin Drug Investig. 2008. PMID: 18345711 Review.

2

Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.

Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Yokoyama K, et al. J Manag Care Pharm. 2007 Apr;13(3):235-44. doi: 10.18553/jmcp.2007.13.3.235. J Manag Care Pharm. 2007. PMID: 17407390 Free PMC article.

3

The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Thomas GN, Chan P, Tomlinson B. Thomas GN, et al. Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004. Drugs Aging. 2006. PMID: 16536636 Review.

4

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.

Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A. Coyle D, et al. Clin Ther. 2007 Jul;29(7):1508-23. doi: 10.1016/j.clinthera.2007.07.029. Clin Ther. 2007. PMID: 17825702

5

Moderately Elevated Blood Pressure: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment. Swedish Council on Health Technology Assessment. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2004 Oct. SBU Yellow Report No. 170/1+2. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2004 Oct. SBU Yellow Report No. 170/1+2. PMID: 28876790 Free Books & Documents. Review.

6

Moderately Elevated Blood Pressure: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment. Swedish Council on Health Technology Assessment. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Sep. SBU Yellow Report No. 170/1U. Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Sep. SBU Yellow Report No. 170/1U. PMID: 28876740 Free Books & Documents. Review.

7

What have we learned from the current trials?

Abbott KC, Bakris GL. Abbott KC, et al. Med Clin North Am. 2004 Jan;88(1):189-207. doi: 10.1016/s0025-7125(03)00129-9. Med Clin North Am. 2004. PMID: 14871059 Review.

8

Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect.

Meredith PA. Meredith PA. Am J Cardiovasc Drugs. 2005;5(3):171-83. doi: 10.2165/00129784-200505030-00004. Am J Cardiovasc Drugs. 2005. PMID: 15901205 Review.

9

Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?

Weir MR. Weir MR. Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019. Clin Ther. 2007. PMID: 18035185 Review.

10

Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.

Boersma C, Voors AA, Visser ST, de Jong-van den Berg LT, Postma MJ. Boersma C, et al. Am J Cardiovasc Drugs. 2010;10(1):49-54. doi: 10.2165/11319570-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20104934

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

79 results

Results by year